阻断肿瘤内CD8+ T细胞:Treg串扰可提高PD-1免疫疗法的疗效

IF 48.8 1区 医学 Q1 CELL BIOLOGY
Shannon N. Geels, Alexander Moshensky, Rachel S. Sousa, Claire Murat, Matias A. Bustos, Benjamin L. Walker, Rima Singh, Stacey N. Harbour, Giselle Gutierrez, Michael Hwang, Thorsten R. Mempel, Casey T. Weaver, Qing Nie, Dave S.B. Hoon, Anand K. Ganesan, Shivashankar Othy, Francesco Marangoni
{"title":"阻断肿瘤内CD8+ T细胞:Treg串扰可提高PD-1免疫疗法的疗效","authors":"Shannon N. Geels, Alexander Moshensky, Rachel S. Sousa, Claire Murat, Matias A. Bustos, Benjamin L. Walker, Rima Singh, Stacey N. Harbour, Giselle Gutierrez, Michael Hwang, Thorsten R. Mempel, Casey T. Weaver, Qing Nie, Dave S.B. Hoon, Anand K. Ganesan, Shivashankar Othy, Francesco Marangoni","doi":"10.1016/j.ccell.2024.05.013","DOIUrl":null,"url":null,"abstract":"<p>PD-1 blockade unleashes potent antitumor activity in CD8<sup>+</sup> T cells but can also promote immunosuppressive T regulatory (Treg) cells, which may worsen the response to immunotherapy. Tumor-Treg inhibition is a promising strategy to improve the efficacy of checkpoint blockade immunotherapy; however, our understanding of the mechanisms supporting tumor-Tregs during PD-1 immunotherapy is incomplete. Here, we show that PD-1 blockade increases tumor-Tregs in mouse models of melanoma and metastatic melanoma patients. Mechanistically, Treg accumulation is not caused by Treg-intrinsic inhibition of PD-1 signaling but depends on an indirect effect of activated CD8<sup>+</sup> T cells. CD8<sup>+</sup> T cells produce IL-2 and colocalize with Tregs in mouse and human melanomas. IL-2 upregulates the anti-apoptotic protein ICOS on tumor-Tregs, promoting their accumulation. Inhibition of ICOS signaling before PD-1 immunotherapy improves control over immunogenic melanoma. Thus, interrupting the intratumor CD8<sup>+</sup> T cell:Treg crosstalk represents a strategy to enhance the therapeutic efficacy of PD-1 immunotherapy.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":null,"pages":null},"PeriodicalIF":48.8000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy\",\"authors\":\"Shannon N. Geels, Alexander Moshensky, Rachel S. Sousa, Claire Murat, Matias A. Bustos, Benjamin L. Walker, Rima Singh, Stacey N. Harbour, Giselle Gutierrez, Michael Hwang, Thorsten R. Mempel, Casey T. Weaver, Qing Nie, Dave S.B. Hoon, Anand K. Ganesan, Shivashankar Othy, Francesco Marangoni\",\"doi\":\"10.1016/j.ccell.2024.05.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>PD-1 blockade unleashes potent antitumor activity in CD8<sup>+</sup> T cells but can also promote immunosuppressive T regulatory (Treg) cells, which may worsen the response to immunotherapy. Tumor-Treg inhibition is a promising strategy to improve the efficacy of checkpoint blockade immunotherapy; however, our understanding of the mechanisms supporting tumor-Tregs during PD-1 immunotherapy is incomplete. Here, we show that PD-1 blockade increases tumor-Tregs in mouse models of melanoma and metastatic melanoma patients. Mechanistically, Treg accumulation is not caused by Treg-intrinsic inhibition of PD-1 signaling but depends on an indirect effect of activated CD8<sup>+</sup> T cells. CD8<sup>+</sup> T cells produce IL-2 and colocalize with Tregs in mouse and human melanomas. IL-2 upregulates the anti-apoptotic protein ICOS on tumor-Tregs, promoting their accumulation. Inhibition of ICOS signaling before PD-1 immunotherapy improves control over immunogenic melanoma. Thus, interrupting the intratumor CD8<sup>+</sup> T cell:Treg crosstalk represents a strategy to enhance the therapeutic efficacy of PD-1 immunotherapy.</p>\",\"PeriodicalId\":9670,\"journal\":{\"name\":\"Cancer Cell\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":48.8000,\"publicationDate\":\"2024-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Cell\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ccell.2024.05.013\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ccell.2024.05.013","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

PD-1阻断可释放CD8+ T细胞的强大抗肿瘤活性,但也会促进免疫抑制性T调节(Treg)细胞,从而可能会恶化对免疫疗法的反应。抑制肿瘤-Treg是提高检查点阻断免疫疗法疗效的一种很有前景的策略;然而,我们对PD-1免疫疗法期间支持肿瘤-Treg的机制的了解还不全面。在这里,我们发现在黑色素瘤小鼠模型和转移性黑色素瘤患者中,PD-1阻断会增加肿瘤-Tregs。从机理上讲,Treg 的积累并不是由 PD-1 信号的 Treg 内在抑制引起的,而是取决于活化的 CD8+ T 细胞的间接作用。CD8+ T细胞产生IL-2,并与小鼠和人类黑色素瘤中的Tregs共定位。IL-2 上调肿瘤-Tregs 上的抗凋亡蛋白 ICOS,促进它们的聚集。在PD-1免疫疗法之前抑制ICOS信号传导可改善对免疫原性黑色素瘤的控制。因此,阻断肿瘤内CD8+ T细胞与Treg的串扰是提高PD-1免疫疗法疗效的一种策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy

Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy

PD-1 blockade unleashes potent antitumor activity in CD8+ T cells but can also promote immunosuppressive T regulatory (Treg) cells, which may worsen the response to immunotherapy. Tumor-Treg inhibition is a promising strategy to improve the efficacy of checkpoint blockade immunotherapy; however, our understanding of the mechanisms supporting tumor-Tregs during PD-1 immunotherapy is incomplete. Here, we show that PD-1 blockade increases tumor-Tregs in mouse models of melanoma and metastatic melanoma patients. Mechanistically, Treg accumulation is not caused by Treg-intrinsic inhibition of PD-1 signaling but depends on an indirect effect of activated CD8+ T cells. CD8+ T cells produce IL-2 and colocalize with Tregs in mouse and human melanomas. IL-2 upregulates the anti-apoptotic protein ICOS on tumor-Tregs, promoting their accumulation. Inhibition of ICOS signaling before PD-1 immunotherapy improves control over immunogenic melanoma. Thus, interrupting the intratumor CD8+ T cell:Treg crosstalk represents a strategy to enhance the therapeutic efficacy of PD-1 immunotherapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer Cell
Cancer Cell 医学-肿瘤学
CiteScore
55.20
自引率
1.20%
发文量
179
审稿时长
4-8 weeks
期刊介绍: Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信